Journal of Cardiobiology
Research Article
Clinician Perspectives on Lipid Management and Antiplatelet Strategies in Acute Coronary Syndrome with A Special Focus On Rosuvastatin in Indian Settings
Manjula S* and Krishna Kumar M
Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India
*Address for Correspondence:Dr Manjula S, Department of Medical Services, Micro Labs Limited,
Bangalore, Karnataka. E-mail Id: drmanjulas@gmail.com
Submission: 16 April, 2026
Accepted: 06 May, 2026
Published: 08 May, 2026
Copyright: © 2026 Manjula S, et al. This is an open access article
distributed under the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Keywords:Acute coronary syndrome; Rosuvastatin; Dual antiplatelet therapy; Lipidlowering
therapy
Abstract
Objective: To assess clinician perspectives and preferences regarding lipid
management and antiplatelet strategies in patients with acute coronary syndrome
(ACS).
Methodology: In this cross-sectional study, a 22-item, multiple-response questionnaire was utilized to gather clinicians’ opinions on current practices, clinical observations, and experiences regarding lipid-lowering and antiplatelet strategies in the routine management of ACS. Data was analyzed using descriptive statistics, with categorical variables presented as percentages and visualized through pie and bar charts in Excel.
Results: The survey included 615 respondents. The majority of clinicians (94.47%) reported prescribing rosuvastatin as the preferred lipid-lowering agent for patients with hyperlipidemia and comorbid hypertension or diabetes. About 74% of the experts favored dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin as the initial antiplatelet strategy for ACS. Approximately 45% opined that DAPT (clopidogrel plus aspirin) is typically continued for 12 months in patients who have undergone percutaneous coronary intervention (PCI) with stent placement. Highintensity statin monotherapy was reported by 38% of participants as the preferred lipid management strategy in post-ACS patients. Approximately 37% of respondents stated that rosuvastatin monotherapy was their preferred approach for high-risk patients (ACS with diabetes), while 36% reported rosuvastatin plus ezetimibe as the preferred choice. Additionally, 41% of experts indicated that the combination of rosuvastatin and ezetimibe is often recommended for patients with LDL-C >70 mg/dL and high atherosclerotic cardiovascular disease (ASCVD) risk.
Conclusion: This study highlights a strong preference for rosuvastatin-centered lipid management and clopidogrel-based DAPT among Indian clinicians treating ACS. High-intensity statin therapy and 12-month DAPT following PCI emerge as common practice patterns. Combination therapy with rosuvastatin and ezetimibe is frequently recommended for patients with elevated LDL-C and high ASCVD risk
Methodology: In this cross-sectional study, a 22-item, multiple-response questionnaire was utilized to gather clinicians’ opinions on current practices, clinical observations, and experiences regarding lipid-lowering and antiplatelet strategies in the routine management of ACS. Data was analyzed using descriptive statistics, with categorical variables presented as percentages and visualized through pie and bar charts in Excel.
Results: The survey included 615 respondents. The majority of clinicians (94.47%) reported prescribing rosuvastatin as the preferred lipid-lowering agent for patients with hyperlipidemia and comorbid hypertension or diabetes. About 74% of the experts favored dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin as the initial antiplatelet strategy for ACS. Approximately 45% opined that DAPT (clopidogrel plus aspirin) is typically continued for 12 months in patients who have undergone percutaneous coronary intervention (PCI) with stent placement. Highintensity statin monotherapy was reported by 38% of participants as the preferred lipid management strategy in post-ACS patients. Approximately 37% of respondents stated that rosuvastatin monotherapy was their preferred approach for high-risk patients (ACS with diabetes), while 36% reported rosuvastatin plus ezetimibe as the preferred choice. Additionally, 41% of experts indicated that the combination of rosuvastatin and ezetimibe is often recommended for patients with LDL-C >70 mg/dL and high atherosclerotic cardiovascular disease (ASCVD) risk.
Conclusion: This study highlights a strong preference for rosuvastatin-centered lipid management and clopidogrel-based DAPT among Indian clinicians treating ACS. High-intensity statin therapy and 12-month DAPT following PCI emerge as common practice patterns. Combination therapy with rosuvastatin and ezetimibe is frequently recommended for patients with elevated LDL-C and high ASCVD risk